Ind-Swift Limited (NSE:INDSWFTLTD)

Market Cap	866.63M
Revenue (ttm)	5.06B
Net Income (ttm)	643.92M
Shares Out	n/a
EPS (ttm)	11.90
PE Ratio	1.35
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,773
Average Volume	89,914
Open	16.97
Previous Close	16.05
Day's Range	15.90 - 16.97
52-Week Range	12.00 - 34.70
Beta	-0.87
RSI	53.74
Earnings Date	Jun 25, 2025

About Ind-Swift

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicine...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1983
• Employees: 1,054
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLTD

Financial Performance

In 2023, Ind-Swift's revenue was 5.02 billion, an increase of 22.22% compared to the previous year's 4.11 billion. Earnings were 142.31 million, a decrease of -45.34%.